Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug
MT Newswires Live01-08
Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) said China's National Medical Products Administration has approved the marketing of Retlirafusp alfa Injection, an independently developed Class 1 innovative drug, according to a Wednesday Hong Kong bourse filing.
Hong Kong-listed shares of the firm were down more than 1% in Thursday's late-morning trade.
The drug is approved for use in combination with fluorouracil and platinum-based chemotherapy as a first-line treatment for PD-L1-positive locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
